This trial has been completed.

Conditions drug abuse, schizophrenia, bipolar disorder, major depressive disorder
Treatments contingency management, non contingent control condition
Sponsor University of Washington
Collaborator National Institute on Drug Abuse (NIDA)
Start date April 2008
End date July 2012
Trial size 176 participants
Trial identifier NCT00809770, R01DA022476, R01DA022476-01, RDA022476A


The purpose of this study is to determine the effectiveness of a behavioral treatment, contingency management, in reducing stimulant use in persons with serious mental illness.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Contingency management
contingency management
Opportunities to earn rewards are given three times a week for 12 weeks contingent on negative urine analyses indicating drug abstinence
Non Contingent Control Condition
non contingent control condition
Opportunities to draw for rewards are provided three times a week for 12 weeks for providing urine analysis. Opportunities to earn rewards are not based on urine analysis results.

Primary Outcomes

Stimulant drug use as measured by urine analysis
time frame: Treatment phase: 12 weeks (3 measurements a week), Follow Up Phase: 3 months (1 measuresment a month)

Secondary Outcomes

Self report drug use
time frame: Measured monthly througout the study
Other drug use as measured by urine analysis
time frame: Treatment phase: 12 weeks (3 measurements a week), Follow Up Phase: 3 months (1 measuresment a month)
Symptoms of mental illness
time frame: Monthly throughout the study
Community outcomes (jail bookings, ER visits, mental health outcomes)
time frame: The entire study period and three months prior and after study involvement

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Enrolled patient at Community Psychiatric Clinic (CPC), a large mental health center in urban Seattle, Washington; - Between 18 and 65 years of age; - Diagnosis of of methamphetamine, amphetamine(illegal), or cocaine dependence or abuse; - CPC medical record diagnosis of schizophrenia, schizoaffective disorder, bipolar I or II, or recurrent major depressive disorder - Stimulant drug use one month before enrollment; - Ability to understand written and spoken English; - CPC clinical case manager must affirm the potential participant's ability to provide informed consent and clinical appropriateness (i.e., safety/severity of mental/substance/ physical health) to participate in the study. Exclusion Criteria: - Any medical/psychiatric condition, or severity of that condition, that, in the opinion of Dr. Ries, the PI, would compromise safe study participation - Chart defined organic brain disorder or dementia; - Current participation in a methadone maintenance program; - Any other circumstances that in the PI's opinion precludes safe study participation.

Additional Information

Official title Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill
Principal investigator Richard K Ries, MD
Description This study will evaluate the efficacy of a twelve week contingency management (CM) intervention for treating psycho-stimulant substance abuse when delivered in the context of a community mental health center (CMHC) setting for adults suffering from serious mental illness (SMI). The CM paradigm to be used is one which has been shown effective in several recent large clinical trials, using the variable magnitude of reinforcement procedure. The reinforcers will be vouchers or actual items useful for day to day living in this population. Two hundred SMI participants with co-occurring stimulant disorders will be recruited from a large urban CMHC and randomized to receive either the active CM paradigm plus treatment as usual (TAU), or TAU which will include the delivery of reinforcement for study involvement (reinforcement that is not contingent on drug abstinence). The primary outcome is change in psycho-stimulant use (methamphetamine, amphetamine and/or cocaine). Secondary outcomes include: changes in use of other illegal drugs or alcohol; changes in CMHC treatment adherence and follow-through; changes in psychiatric symptoms, quality of life, and community outcomes (homelessness, incarcerations, etc.). Additional outcomes to be measured include changes in drug craving, stage of change, nicotine use, and HIV risk status. The study involves two phases, the 12 week treatment phase, where CM and control treatments are delivered, as well as a 3 month follow up phase.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by University of Washington.